Study of two drugs for advanced skin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of cutaneous T-cell lymphoma.
- Your disease is measurable and is at stage IB–IVB.
- You have already tried at least one prior treatment (like radiation, retinoids, or chemotherapy) and it didn't help or it stopped working.
- You are able to do daily activities (ECOG 0–2).
- Your blood counts and organ function (like liver, kidney, heart) are within acceptable ranges.
- You are not pregnant or nursing.
- You do not have active infections or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
This trial tests a new investigational drug (DT-7012) for people with a type of skin lymphoma that hasn't responded to standard treatments. The drug is given as an infusion and aims to boost your immune system to fight the cancer.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
This trial tests a combination of three drugs — golidocitinib, azacitidine, and chidamide — for people with peripheral T-cell lymphoma who cannot receive standard intensive chemotherapy. The goal is to see if this combination can help control the lymphoma with fewer side effects.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hear when a new Cutaneous T-cell Lymphoma (CTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.